Novartis taps Penn University for cancer immunotherapy
This article was originally published in Scrip
Novartis has licensed a clinical candidate for cancer immunotherapy and set up a broader cellular therapy alliance with the University of Pennsylvania (Penn).
You may also be interested in...
Novartis' New Oncology CEO Liz Barrett Charts A Course, But It Will Require Jump-Starting New Brands
Liz Barrett joined Novartis in February after leading Pfizer's oncology unit, taking over leadership of the business at a time of transition and tasked with building new blockbusters as old reliable work engines mature. She talked to Scrip about her plans for Novartis Oncology at ASCO.
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.